Alexza's Migraine Drug Meets Endpoint in Phase II Trial
Posted on: Tuesday, 4 March 2008, 09:01 CST
Alexza Pharmaceuticals has reported positive top-line results from its 168 patient Phase IIa trial of AZ-104 or Staccato loxapine in patients with migraine headache.
Two doses of AZ-104, 2.5 and 5mg, met the primary endpoint of two-hour pain-relief compared to placebo. The company has said that statistically significant improvements in pain response were observed in 76.7% of patients at the 5mg dose (p = 0.02), 79.1% of patients at the 2.5mg dose (p = 0.01) and 67.4% of patients at the 1.25mg dose (p = 0.18), compared to 51.3% of patients receiving placebo.
Using survival analysis for pain relief response, all three dose groups were statistically superior to placebo during the four-hour post-treatment time period that the patients remained in the clinic.
Source: Datamonitor
Related Articles
- Primary Children's Medical Center Draws First Pediatric Patient Dose with RIVA
- CHOC Children's Draws First Patient Dose With RIVA System
- UK's NICE Recommends Spinal Cord Stimulation for Patients With Chronic Neuropathic Pain
- Athersys Initiates Patient Dosing in Phase I Acute Myocardial Infarction Study
- Chelsea Therapeutics Begins Patient Dosing in Second Pivotal Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension
- Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and Was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
- Immunomedics Begins Patient Dosing in Veltuzumab Phase I/II Trial
- Prana Completes Final Patient Dosing in Alzheimer's Phase II Trial
- Medivation Announces First Patient Dosed in Phase II Trial With Dimebon for Treating Alzheimer's Disease
- Cubist Pharmaceuticals Announces the End of Patient Dosing in HepeX-B(TM) Hepatitis B Phase 2 Trial
 |
 |
User Comments (0)
RSS Feeds